Bing

Aug. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a New Drug ... products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity …
Financial Content · 8/25/2015
Amgen
Amgen Inc. ( AMGN) and Gilead Sciences, Inc. ( GILD) are two California based bio-pharmaceutical companies that provide human therapeutics. Both companies focus and develop treatments and medicines to combat against different cancers, kidney …
NASDAQ · 8/14/2015
LONDON, Aug 28 (Reuters) - European equity futures pointed to a marginally higher open for stock markets on Friday ... 4332.HK - news) 's AMGN.O Repatha drug for patients with hereditary forms of high cholesterol …
Yahoo Finance UK and Ireland · 8/28/2015
Amgen Inc. (AMGN - Analyst Report) and Gilead Sciences, Inc. (GILD - Analyst Report) are two California based bio-pharmaceutical companies that provide human therapeutics. Both companies focus and develop treatments and medicines to combat …
ZACKS · 8/14/2015
Biotech giant Amgen (NASDAQ:AMGN) won U.S. approval for its pricey cholesterol-lowering ... at 10:07 a.m. in New York. The stock has gained 13% over the past year. Proactive Investors North America Inc, trades as …
Proactiveinvestors · 8/28/2015
pricey cholesterol
Amgen (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by analysts at Deutsche Bank in a research report issued to clients and investors on Thursday. They currently have a $192.00 price target on the medical research company’s stock.
wkrb13.com · 6/12/2015
Amgen (NASDAQ:AMGN) was upgraded by Zacks from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Market Beat.com reports. The firm currently has a $184.00 target price on the medical research company’s stock.
Watch List News · 7/25/2015
The biotechnology sector can be a land of immense spoils and incredible heartbreak. It’s not uncommon to see small and midsized biotech companies swing wildly in each direction because of clinical trial data or a decision by the Food and Drug …
INSIDER MONKEY · 4/7/2013
Amgen (NASDAQ: AMGN) today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock. Amgen also announced a public offering of its senior notes, the proceeds of which will be used to fund the ...
StreetInsider · 11/7/2011
New York, NY - (ACCESSWIRE) - 10/29/2013 - Equity Profile Report initiates its NASDAQ Active Stock Watch List adding American Capital Agency Corp. (NASDAQ:AGNC), Patterson-UTI Energy Inc. (NASDAQ:PTEN), Amgen Inc. (NASDAQ:AMGN), and …
4 Traders · 10/29/2013

Amgen

Company
Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Locate…
Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
Data from: Wikipedia